drugset / Trial / NCT02836821

Effect of Rifampicin on the Pharmacokinetics of Apatinib

NCT02836821

Phase 1 Completed 20 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to investigate potential pharmacokinetic interaction in healthy volunteers when apatinib is administered in combination with rifampicin. Secondary objective is evaluating the safety and tolerability of apatinib alone and when co-administered with rifampicin.

Timeline

Start
2016-05
Primary completion
2017-02
Completion
2017-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifampin Small molecule 600 mg Oral
Subject Rivoceranib Small molecule 750 mg Oral

Indications